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OBJECTIVES In the present study, we tested whether a nitrate-free interval is able to prevent increases in
vascular superoxide (O2
•2) and the development of hypersensitivity to vasoconstrictors and
whether this may result in restoration of vascular nitroglycerin (NTG) sensitivity.
BACKGROUND Intermittent NTG-patch treatment (12 h patch on/patch off) has been shown to increase
ischemic periods in patients with stable coronary arteries, suggesting a rebound-like situation
during the patch-off period. Recently, we demonstrated that long-term treatment with NTG
induces tolerance, which was in part related to increases in vascular O2
•2 and increased
vasoconstrictor sensitivity.
METHODS New Zealand white rabbits received a continuous application of NTG patches (0.4 mg/h) or
an intermittent application of NTG patches (12 h patch on, 12 h patch off) for three days.
Isometric tension studies were performed with aortic rings, and vascular O2
•2 was estimated
using lucigenin-derived chemiluminescence (5 mmol/liter). Expression of the copper/zinc
(Cu/Zn) superoxide dismutase (SOD) was assessed by Western blotting, and SOD activity
was measured by autooxidation of 6-hydroxydopamine.
RESULTS Continuous treatment with NTG caused tolerance to NTG, cross-tolerance to the
endothelium-dependent vasodilator acetylcholine, increased vascular O2
•2, reduced Cu/Zn
SOD expression and increased sensitivity to vasoconstrictors such as phenylephrine, serotonin
and angiotensin II. On/off treatment with NTG improved tolerance, corrected endothelial
dysfunction and decreased vascular O2
•2. In addition the reduction in SOD expression was
less pronounced, whereas increases in the sensitivity to vasoconstrictors such as phenylephrine
and serotonin remained nearly unchanged.
CONCLUSIONS Enhanced vasoconstrictor sensitivity may explain, at least in part, the rebound phenomena
observed in patients during a 12-h NTG patch-off period. (J Am Coll Cardiol 2000;36:
628–34) © 2000 by the American College of Cardiology
The therapeutic benefit of the organic nitrates is limited by
the development of tolerance shortly after the onset of
treatment (1). Intermittent administration of patches, al-
lowing for an 8- to 12-h nitrate-free interval, has been
demonstrated to avoid tolerance (2–4), with the disadvan-
tage of lacking protection during this period. Another
potential problem of the nitrate-free period can be the
development of rebound ischemia. In patients with stable
angina pectoris, Freedman et al. (5) have shown an increase
in the duration of silent ischemia in the nitroglycerin
(NTG)-treated group as compared with the placebo group.
The authors suggested that their observations may be
compatible with rebound ischemia during the nitrate-free
period. These data go along with recent results demonstrat-
ing a decreased anginal threshold after NTG patch removal
(6,7). Using an experimental model of nitrate tolerance, we
have previously shown that continuous NTG treatment for
three days led to a marked attenuation of the vasodilator
potency and efficacy of NTG and to endothelial dysfunction
associated with increased vascular superoxide (O2
•2) levels.
This is due to activation of O2
•2-producing enzymes (8–10)
and decreased activity and expression of the radical scaven-
ger enzyme copper/zinc (Cu/Zn) superoxide dismutase
(SOD) (11). We have also demonstrated an increased
sensitivity of the nitrate-tolerant vasculature to vasocon-
strictors such as phenylephrine, serotonin and angiotensin II
(12). Similarly, NTG treatment induced enhanced vasocon-
strictor responses to vasoconstrictor stimuli, such as angio-
tensin II and phenylephrine, in the forearm circulation (13)
and coronary vasoconstriction in response to the
endothelium-dependent vasodilator acetylcholine (ACh).
This suggests that NTG-induced changes in vasoconstrictor
sensitivity may indeed represent a clinically relevant phe-
nomenon.
On the basis of these considerations, the present study
was designed to study the effects of 12-h patch on/patch off
NTG treatment on the sensitivity of the vasculature to
endothelium-dependent and -independent vasodilators, on
vasoconstrictor sensitivity and on vascular O2
•2 production
in a well-characterized animal model of nitrate tolerance. In
addition, we tested to what extent a 12-h nitrate-free
interval was sufficient to restore the reduced vascular SOD
activity and Cu/Zn SOD expression.
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METHODS
Animal model. New Zealand White rabbits of either
gender (weight 3 to 6 kg) were studied. A region on the
dorsal thorax or between the scapulae was shaved and a
NTG patch was applied to the skin. The NTG patch was
changed every morning. The rabbits were studied after three
days of continuous NTG therapy (n 5 15) or after a
three-day period of 12-h patch on/patch off NTG admin-
istration (n 5 18). In these animals, the last patch was
removed 12 h before experimentation. Control rabbits (n 5
16) received no NTG. On the morning of the study day, an
intravenous injection of 1,000 U heparin was administered,
followed by a lethal dose of pentobarbital. The chest was
then rapidly opened, and the descending thoracic aorta was
removed.
Vessel preparation and organ chamber experiments. The
aorta was placed in chilled Krebs buffer and cleaned of
excessive adventitial tissue. Eight 5-mm rings of thoracic
aorta were suspended in individual organ chambers (25 ml)
filled with carbogen-equilibrated Krebs buffer of the follow-
ing composition (mmol/liter): NaCl 118.3, KCl 4.69,
CaCl2 1.87, MgSO4 1.20, K2HPO4 1.03, NaHCO3 25.0
and glucose 11.1 (pH 7.40). During the next hour, the rest
tension was increased to optimize contractions to KCl (80
mmol/liter), as described. This optimal state, occurred at 5
g rest tension for both NTG-tolerant and control aortic
rings. Control and tolerant rings were then preconstricted
with phenylephrine (0.1 to 0.3 mmol/liter). When the tone
had reached a stable plateau, NTG or ACh was applied to
the organ baths in cumulative concentrations (1 nmol/liter
to 3 mmol/liter in semilogarithmic concentration steps), and
relaxant responses were recorded continuously.
Concentration–response curves were generated for phen-
ylephrine, angiotensin II and serotonin and quantified as the
percentage of contractions to a maximally depolarizing
concentration (80 mmol/liter) of KCl, as described previ-
ously (13).
Measurement of superoxide production in endothelium-
intact vascular rings. Superoxide production in
endothelium-intact aortic rings from control and NTG-
treated animals was measured using lucigenin-derived
chemiluminescence (LDCL). The details of this method
have been reported previously (14). Briefly, after prepara-
tion, the rings were equilibrated for 30 min at 37°C in
modified Krebs buffer at pH 7.4, containing 20 mmol/liter
of N-(2-hydroxyethyl)piperazine-N9-(2-ethanesulfonic
acid) (HEPES). Scintillation vials containing 700 ml of
Krebs/HEPES buffer with lucigenin (5 mmol/liter) were
placed into a scintillation counter switched to the out-of-
coincidence mode. After 15 min, background counts were
recorded, and a vascular ring was then added to the vial.
Scintillation counts were recorded after an additional
15 min, and the respective background counts were sub-
tracted. The vessels were then dried for 24 h at 90°C,
allowed to cool and weighed.
To address the influence of endothelial nitric oxide
synthase (NOS III)-derived nitric oxide (NO) on the
vascular LDCL signal, the vessels were incubated for
30 min at 37°C with NG-methyl-L-arginine (L-NMA, 1
mmol/liter), as described recently (14).
SOD activity assay. To assess the SOD activity of control
and tolerant aortic rings, they were homogenized (10%
wt/vol) in 50 mmol/liter KH2PO4 and 0.05 mmol/liter
EDTA (pH 6.5), as described (11). The homogenates were
cleaned of debris by centrifugation at 10,000 3 g for 20 min.
Thereafter, SOD activity was assessed in the supernatants
by measuring the rate of SOD-sensitive autooxidation of
6-hydroxydopamine (6-HDOPA). Autooxidation of
6-HDOPA is catalyzed by O2
•2, yielding a red adreno-
chrome (lmax 490 nm), and is inhibited by SOD in a
concentration-dependent fashion. The aortic extracts (10 to
100 mg protein in 0.9 ml homogenization buffer) were
incubated at room temperature in plastic cuvettes. The
reactions were started by addition of 6-HDOPA (final
concentration 0.2 mmol/liter; 0.1 ml of 2-mmol/liter stock
solution dissolved in N2-gassed distilled water). The in-
crease in absorbance at 490 nm was continuously monitored
for 3 min in a double-beam spectrophotometer. In the
absence of tissue extracts, the absorbance increased by
0.10 6 0.03 U/min due to spontaneous oxidation of
6-HDOPA. This rate was decreased in the presence of
known amounts of pure Cu/Zn SOD (from bovine eryth-
rocytes, Sigma, Deisenhofen, Germany). An apparently
linear concentration–rate relation was observed from 0.1 to
0.5 U SOD.
Western blot analysis. Rat aortic tissue was homogenized
in ice-cold homogenization buffer containing (in mmol/
liter) NaCl 99.01, KCl 4.69, CaCl2 2.5, MgSO4 1.2,
NaHCO3 25, K2HPO4 1.03, Na-HEPES 20, D-glucose
11.1, aprotinin 0.0015, leupeptin 0.0107, pepstatin 0.0102
and PMSF 0.0028, using a glas/glas homogenizer. The
homogenate was centrifuged at 3,000 3 g for 5 min to
remove insoluble material. A total of 15 mg protein was
then subjected to sodium dodecyl sulfate-PAGE and trans-
ferred to nitrocellulose membranes (Bio-Rad, Mu¨nchen,
Germany). Immunoblotting was performed for 2 h at room
temperature with a polyclonal sheep antibody to human
Abbreviations and Acronyms
ACh 5 acetylcholine
Cu/Zn 5 copper/zinc
EC50 5 50% effective concentration
6-HDOPA 5 6-hydroxydopamine
LDCL 5 lucigenin-derived chemiluminescence
L-NMA 5 NG-methyl-L-arginine
NOS III 5 endothelial nitric oxide synthase
NTG 5 nitroglycerin
O2
•2 5 superoxide
SOD 5 superoxide dismutase
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erythrocyte Cu/Zn SOD (dilution 1:3000, Transduction
Laboratories, Lexington, Kentucky). Immunodetection was
accomplished with an antisheep secondary antibody (1:2000
dilution, Upstate Biotechnology, Lake Placid, New York)
and the enhanced chemiluminescence kit (Amersham,
Buckinghamshire, United Kingdom). Quantification of the
16-kDa Cu/Zn SOD subunits was performed by densitom-
etry, as described recently (11). The signals were integrated,
and the results expressed as percent of the control signals.
Materials. All chemicals were purchased from Sigma.
Statistical analyses. Results are expressed as the mean
value 6 SEM. The 50% effective concentration (EC50)
value for each experiment was obtained by logit transfor-
mation. To compare O2
•2 production, SOD activity and
SOD expression in vessels from control animals and animals
treated with continuous and intermittent NTG, one-way
analysis of variance was employed. Comparisons of vascular
responses were performed using multivariate analysis of
variance, with animal treatment as the independent vari-
ables and percent relaxation and EC50 as the dependent
variables. The Scheffe´ post hoc test was used to examine
differences between groups when significance (p , 0.05)
was indicated.
RESULTS
Effects of three-day continuous or intermittent NTG
administration in vivo on the in vitro vasorelaxation to
NTG and ACh. As previously demonstrated (6), con-
tinuous in vivo treatment for three days with NTG
patches markedly impaired both the potency and efficacy
of NTG to produce vasorelaxation in subsequent organ
chamber studies (Fig. 1, Table 1). This impairment was
less pronounced in the aortas from animals treated with a
nitrate-free interval. Also, the potency and efficacy of the
endothelium-dependent vasodilator ACh were impaired
in vessels from NTG-treated animals (p , 0.05) (Fig. 1,
Table 1). A nitrate-free interval almost completely pre-
vented the development of endothelial dysfunction (Fig.
1, Table 1).
Effects of three-day NTG continuous or intermittent
NTG administration in vivo on the in vitro sensitivity to
vasoconstrictors. As shown previously, treatment of rab-
bits for three days with NTG caused a significant increase in
sensitivity to vasoconstrictors such as angiotensin II, phen-
ylephrine, serotonin and potassium chloride (13). In animals
treated with a nitrate-free interval, the hypersensitivity to
angiotensin II and partially to KCl was corrected, whereas
constrictions to phenylephrine were unchanged. Interest-
ingly, constrictions to serotonin were increased (Fig. 2,
Table 2).
Effects of a nitrate-free interval on NTG-induced in-
creases in vascular superoxide production. As demon-
strated previously (6), O2
•2 production (estimated with
LDCL) was increased approximately twofold in
endothelium-intact aortic rings from nitrate-treated animals
as compared with those from untreated animals (Fig. 3). A
nitrate-free interval significantly reduced vascular O2
•2
steady-state levels, which, however, were still higher than
those of control vessels.
Effects of a nitrate-free interval on NOS-mediated su-
peroxide production. Incubation of vessels from control
animals with the inhibitor of the NOS L-NMA (1023
mol/liter) markedly increased the lucigenin signal, demon-
strating that endothelial-derived NO markedly quenches
Figure 1. Effects of three-day in vivo NTG treatment of rabbits (contin-
uous or 12 h patch on/patch off) on concentration–relaxation curves
generated in vitro with NTG and ACh. Data are presented as the mean
values 6 SEM of six to 10 independent experiments. Solid circles 5 no
treatment; open circles 5 continuous NTG treatment; and solid trian-
gles 5 12-h patch-on/patch-off NTG treatment.
Table 1. Effects of Three-Day Nitroglycerin Treatment of Rabbits (Continuous or 12 h Patch
On/Patch Off) on the Potency and Efficacy of Nitroglycerin or Acetylcholine to Produce
Relaxations in Aortic Rings
In Vivo Pretreatment
Potency EC50 (2log mmol/liter)
Efficacy (% Maximal
Relaxation)
NTG ACh NTG ACh
None (control) 7.63 6 0.08 7.32 6 0.03 95 6 2 87 6 2
Continuous NTG 6.72 6 0.12* 6.77 6 0.11* 68 6 4* 70 6 4*
12-h Patch-on/patch-off NTG 7.40 6 0.04 7.15 6 0.11 84 6 2*† 85 6 3
*p , 0.05 vs. control group. †p , 0.05 vs. control group. Each value (mean 6 SEM) has been calculated from five to nine
experiments.
ACh 5 acetylcholine; EC50 5 50% effective concentration; NTG 5 nitroglycerin.
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the lucigenin signal (14). In the setting of tolerance, the
basal lucigenin signal was increased twofold, as compared to
control vessels. Preincubation of these tolerant vessels with
L-NMA paradoxically decreased LDCL, indicating that in
the setting of tolerance, NOS III may represent a significant
O2
•2 source. In animals treated with a nitrate-free interval,
the basal lucigenin signal was still somewhat increased, but
L-NMA produced increases in LDCL (as in control ves-
sels). This indicates that the 12-h nitrate-free interval is
sufficient to restore the function of NOS III as an NO-
producing enzyme (rather than an O2
•2-producing enzyme)
(Fig. 3).
Effects of a nitrate-free interval on total vascular SOD
activity and on the expression of Cu/Zn SOD. Vascular
SOD activity, as assessed by inhibition of 6-HDOPA
autooxidation, averaged 7.45 6 0.3 U/mg protein in tissue
homogenates from control aortic rings (Fig. 4). In vivo
treatment with NTG reduced SOD activity significantly
(Fig. 4). In animals treated with a nitrate-free interval, SOD
activity was almost completely normalized. Likewise, in vivo
treatment with NTG significantly decreased SOD expres-
sion, which was corrected by a nitrate-free interval (Fig. 5).
DISCUSSION
The present study demonstrates that a 12-h nitrate-free
interval partially restores the sensitivity of the vasculature to
NTG. The improved response to NTG is associated with a
reduction in vascular O2
•2 production secondary to a
restoration of total vascular SOD activity and Cu/Zn SOD
expression. The enhanced vasoconstriction to serotonin and
phenylephrine of vessels from animals treated with a nitrate-
free interval may explain, at least in part, the rebound
phenomena observed during the 12-h patch-off period in
patients with stable coronary artery disease.
Mechanisms underlying nitrate tolerance. The mecha-
nisms underlying nitrate tolerance are likely to be multifac-
torial and may involve neurohumoral activation (15) and
increases in vascular O2
•2 production (9), as well as in-
creased sensitivity to vasoconstrictors (13,16). Recent ani-
Figure 2. Effects of three-day NTG treatment of rabbits (continuous or
12 h patch on/patch off) on concentration–constriction curves generated in
vitro with angiotensin II (Ang II), phenylephrine (Phe), serotonin (5-HT)
and potassium chloride (KCl). Data are presented as the mean values 6
SEM of 10 to 12 experiments. See Figure 1 legend for explanation of
symbols.
Figure 3. Effects of three-day NTG treatment of rabbits (continuous or
12 h patch on/patch off) on vascular O2
•2 production of rabbit aortic tissue
with an intact endothelium. Superoxide production was measured under
control conditions (C) and after the administration of L-NMA (1023
mol/liter, 30-min incubation time). In vessels from control animals,
L-NMA increased vascular steady-state O2
•2 levels, indicating that NO
produced in endothelial cells quenches baseline O2
•2-induced LDCL. In
nitrate-tolerant tissue, basal O2
•2 production was markedly elevated. Here,
L-NMA paradoxically decreased LDCL, indicating that NOS III repre-
sents a significant O2
•2 source. A nitrate-free interval reduced O2
•2 levels
and restored the LDCL-increasing effect of L-NMA, indicating that
intermittent therapy can prevent the uncoupling of NOS III. Data are
presented as the mean values 6 SEM of five to 10 experiments. * Indicates
p , 0.05 versus C; † indicates p , 0.05 versus NTG continuous.
Table 2. Effects of Continuous or Intermittent Nitrate Therapy on 50% Effective Concentration and Maximal Constrictions to
Phenylephrine, Serotonin, Angiotensin II and Potassium Chloride
Potency (EC50) Maximal Constriction (%)
Phe
(2log mol/liter)
5-HT
(2log mol/liter)
Ang II
(2log mol/liter)
KCl
(mmol) Phe 5-HT Ang II KCl
Control 6.40 6 0.05 6.62 6 0.06 8.48 6 0.05 27.7 109 6 2 62 6 7 48 6 2 100
NTG 7.25 6 0.11* 6.76 6 0.11 8.34 6 0.04 18.1* 136 6 5* 83 6 5* 76 6 5* 100
NTG on/off 6.78 6 0.11 6.85 6 0.03 8.18 6 0.07 24.6 140 6 4* 98 6 4*† 59 6 5 100
The sensitivities of phenylephrine (PE), angiotensin II (Ang II), serotonin (5-HT) and potassium chloride (KCl) are expressed as EC50 (concentration that produces 50% maximal
contraction). Data are presented as the mean value 6 SEM of 10 to 15 experiments.
NTG 5 nitroglycerin.
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mal studies have shown that long-term treatment with
NTG patches or NTG infusions leads to endothelial dys-
function. This was associated with increased vascular nico-
tinamide adenine dinucleotide phosphate (NADPH)
oxidase-mediated O2
•2 production (10), decreased activity
and expression of the O2
•2-scavenging enzyme Cu/Zn
SOD (11) and increased sensitivity of the tolerant vascula-
ture to vasoconstrictors such as angiotensin II, phenyleph-
rine and serotonin (13). The present findings confirm and
extend these observations. Treatment of rabbits with NTG
for three days caused a significant shift to the left of the
concentration–response curve for angiotensin II, phenyl-
ephrine, serotonin and KCl. In addition, there was a
significant increase in vascular O2
•2 generation (as deter-
mined with LDCL) and a decreases in total vascular SOD
activity and Cu/Zn SOD expression. In organ chamber
experiments with isolated aortic rings, we also established
attenuation of the responses of the tolerant vasculature to
the endothelium-dependent vasodilator ACh. All these
findings may contribute, at least in part, to the marked
decrease in sensitivity of the vasculature to NTG in response
to continuous treatment.
Nitrate-free interval and vascular superoxide production.
Many strategies have been suggested to prevent the phe-
nomenon of nitrate tolerance, but the only approach that
has gained clinical acceptance is a nitrate-free interval.
Continuous intravenous (17,18), oral (19) or transdermal
(20) treatment with NTG patches causes considerable
tolerance to the preload effects of NTG, to its coronary
vasodilator effects and to the ischemia threshold in patients
with stable angina or myocardial infraction. These phenom-
ena were prevented by a nitrate-free interval ranging from 8
to 12 h. Using 12-h path-on/patch-off NTG treatment, we
observed that the sensitivity of the vasculature to NTG was
markedly improved, O2
•2 production was reduced and
endothelial dysfunction (as assessed by the vascular response
to ACh) was almost completely normalized. The current
study also demonstrates that a nitrate-free interval increases
total vascular SOD activity as well as Cu/Zn SOD expres-
sion, as compared with values obtained from the vessels of
animals receiving continuous NTG treatment.
An interesting observation of the present study was the
LDCL response of the vasculature to the NOS inhibitor
L-NMA. Incubation of control vessels with the NOS
inhibitor markedly increased LDCL, indicating that
endothelial-derived NO quenches LDCL under basal con-
ditions. Vessels from NTG-treated animals, however, pro-
duced a markedly stronger basal LDCL signal, which was
reduced by L-NMA (Fig. 3). These data go along with
preliminary data where NTG infusion in rats increased
NOS III expression and vascular O2
•2 production, which
was blocked by preincubation of tolerant tissue with the
NOS III inhibitor NG-nitro-L-arginine (21). Therefore,
long-term nitrate therapy may cause an uncoupling of NOS
III, resulting in NOS III–mediated O2
•2 production. The
vessels from animals treated intermittently with NTG
showed a L-NMA response, similar to control vessels,
suggesting that a nitrate-free interval of 12 h is sufficient to
prevent the uncoupling of NOS III.
Nitrate-free interval, rebound angina and enhanced sen-
sitivity to vasoconstrictors. Although a nitrate-free inter-
val may restore the sensitivity of arteries and veins to NTG,
several studies have demonstrated that patients with stable
coronary artery disease treated with intermittent transder-
mal nitrate therapy experienced adverse effects for up to 12 h
during the drug-free period. Rebound effects after nitrate
withdrawal have first been described in ammunition workers
Figure 4. Effects of three-day NTG treatment of rabbits (continuous or
12 h patch on/patch off) on SOD activity in aortic homogenates. Contin-
uous in vivo treatment with NTG significantly decreased total vascular
SOD activity. This decrease was prevented by intermittent treatment with
NTG. Data are presented as the mean values 6 SEM of six to eight
separate experiments. *p , 0.05 vs. control.
Figure 5. Upper panel, Representative Western blot illustrating the effects
of three-day NTG treatment of rabbits (continuous or 12 h patch on/patch
off) on the expression of Cu/Zn SOD in aortic homogenates. Lower panel,
Densitometric analyses of four similar Western blots. Continuous in vivo
treatment with NTG for three days caused a significant decrease in protein
expression of Cu/Zn SOD, which was almost completely normalized by
the intermittent treatment. *p , 0.05 vs. control.
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exposed to high concentrations of NTG. They showed a
higher incidence of angina, myocardial infarction and sud-
den cardiac death on the nitrate-free weekends (22). These
conditions may differ from the removal of NTG patches,
but two earlier studies in patients with stable coronary artery
disease suggest the existence of rebound angina during the
nitrate-free interval (23,24). In these studies, NTG patches
were applied for two continuous days, followed by a two-day
nitrate-free period. Interestingly, patients consistently
showed an increase in anginal attacks and sublingual NTG
use on the first day after patch removal.
These observations were confirmed in a more recent
study by Ferratini et al. (25) with transdermal NTG, where
increased nocturnal angina was reported during the NTG
patch-off period. In a multicenter trial, De Mots et al. (26)
reported that 9 of 138 patients treated intermittently with
NTG patches experienced a significant increase in rest
angina during the NTG-free period. Patients receiving
placebo showed no change in rest angina. Intermittent
therapy with NTG patches has also been shown to alter the
diurnal pattern of ischemia, with a loss of overnight nadir
and a decrease in the anginal threshold for 4 to 6 h after
patch removal, all of which suggest rebound ischemia (5).
Results from the Second Transdermal Intermittent Dosing
Evaluation Study (TIDES-II) also showed an increase in
ischemia frequency during patch-off hours after use of low
dose intermittent transdermal NTG (7).
Recent experimental as well as clinical studies have provided
insight into the potential mechanisms underlying these re-
bound phenomena. Abrupt cessation of intravenous NTG
therapy in chronically instrumented dogs induced rebound
constrictions of the large coronary arteries (27). In these
studies, large coronary artery constriction occurred, even in the
absence of an activated circulating renin-angiotensin system,
indicating that long-term NTG therapy may induce intrinsic
abnormalities of the vasculature itself, such as changes in
vasoconstrictor sensitivity. Also, in patients treated with NTG,
removal of the patches was associated with a significant
rebound constriction of the large coronary arteries and a
substantial constrictor response to the endothelium-dependent
vasodilator ACh (28). Acetylcholine induces relaxation by
stimulating the release of NO from endothelial cells, but also
stimulates muscarinic M3 receptors on vascular smooth muscle
cells, thereby inducing vasoconstriction. It remains to be
determined whether an increase in ACh-induced coronary
artery constriction reflects endothelial dysfunction or an in-
creased sensitivity of the smooth muscle cells to vasoconstrictor
agents (28).
The most striking observation of the present studies was
that a 12-h nitrate-free interval failed to correct the hyper-
sensitivity of the vasculature to agonists such as serotonin
and phenylephrine. Serotonin-induced contractions of aor-
tas from animals treated with a nitrate-free interval were
enhanced, as compared with constrictions produced in
nitrate-tolerant tissue. Although the precise mechanisms of
NTG-induced hypersensitivity to vasoconstrictors remain
to be established, more recent experimental studies indicate
that the second messenger protein kinase C may play an
important role in mediating this phenomenon. The in-
creased vasoconstriction to different agonists in the setting
of tolerance is inhibited in vitro by protein kinase C
inhibitors (13). In addition, in vivo treatment with the
protein kinase C inhibitor N-benzoyl-staurosporin has been
shown to prevent NTG-induced vascular hypersensitivity to
thromboxane mimetics and norepinephrine (29).
Study limitations. The dosage of transdermal NTG used
in the present study was 0.4 mg/h. Assuming a uniform
release of the drug, the NTG delivery rate in a 3- to 4-kg
rabbit would average 2 to 3 mg/kg per min. The hemody-
namic changes seen in response to this NTG concentration
include reflex tachycardia (30,31), but no changes with
respect to mean arterial pressure and hind-limb resistance
(30). This particular NTG concentration is not uncom-
monly used in the treatment of patients with unstable
angina or congestive heart failure (when given intravenous-
ly), and may therefore be achieved when nitrates are used
long term. It is difficult to extrapolate the relevance of drug
doses between different species, especially when body sur-
face areas are very different; however, at the very least, one
can conclude that our study may have implications with
respect to intravenous administration and treatment with
high doses of NTG in patients with congestive heart failure.
Clinical implications and conclusions. The present obser-
vations suggest that in our experimental model of nitrate tolerance,
a nitrate-free interval almost completely restores nitrate sensitivity,
reduces oxidative stress, normalizes SOD activity and Cu/Zn
SOD expression, prevents the uncoupling of endothelial NOS
and therefore corrects endothelial dysfunction. However, this
nitrate-free period fails to prevent the development of hypersen-
sitivity to vasoconstrictors, such as serotonin and phenylephrine.
These observations may indicate that NTG-induced sensitization
to vasoconstrictors, rather than decreased sensitivity of the vascu-
lature to NTG, may account for the rebound phenomena ob-
served after NTG withdrawal in intermittent therapy. Because
concomitant treatment with beta-blockers (32) or angiotensin-
converting enzyme inhibitors, or both, has been shown to prevent
rebound phenomena in clinical (33) and experimental studies (27),
the present findings encourage the standard practice of treating
patients with stable angina with a combination of nitrates and
beta-blockers and/or angiotensin-converting enzyme inhibitors.
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